Liver Fibrosis - Pipeline Review, H2 2015
This presentation is the property of its rightful owner.
Sponsored Links
1 / 7

Liver Fibrosis Pipeline Review H2 2015 PowerPoint PPT Presentation


Liver Fibrosis - Pipeline Review, H2 2015 market research report is the latest addition to RnRMarketResearch.com and its collection of Therapeutics business intelligence reports aimed to help take better decisions

Download Presentation

Liver Fibrosis Pipeline Review H2 2015

An Image/Link below is provided (as is) to download presentation

Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.


- - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - -

Presentation Transcript


Liver fibrosis pipeline review h2 2015

Liver Fibrosis - Pipeline Review, H2 2015

By

RnRMarketResearch.com

Publisher Name : Global Markets Direct

Date: 28-Oct-2015

No. of Pages:182

Single User License: US $2000

Browse more Reports on Therapeutics at

http://www.rnrmarketresearch.com/reports/life-sciences/pharmaceuticals/therapeutics .

©http://www.rnrmarketresearch.com/ ; [email protected]

+1 888 391 5441


Liver fibrosis pipeline review h2 2015

Liver Fibrosis - Pipeline Review, H2 2015

This report provides comprehensive information on the therapeutic development for Liver Fibrosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Liver Fibrosis and special features on late-stage and discontinued projects.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

©http://www.rnrmarketresearch.com/ ; [email protected]

+1 888 391 5441


Liver fibrosis pipeline review h2 2015

Liver Fibrosis - Pipeline Review, H2 2015

Companies Discussed/Mentioned in this Research:

Advinus Therapeutics Ltd., AiCuris GmbH & Co. KG, AngionBiomedica Corp., Bioneer Corporation, BiOrion Technologies B.V., BoehringerIngelheim GmbH, Celgene Corporation, Dicerna Pharmaceuticals, Inc., Digna Biotech, S.L., Evotec AG, FibroGen, Inc., Galectin Therapeutics, Inc., Genfit SA, Gilead Sciences, Inc., GNI Group Ltd., HEC Pharm Co., Ltd., Intercept Pharmaceuticals, Inc., Isarna Therapeutics GmbH, KineMed, Inc., LG Life Science LTD., Nitto Denko Corporation, Pfizer Inc., Pharmaxis Limited, Promedior, Inc., Promethera Biosciences S.A., ProMetic Life Sciences Inc., RuiYi Inc., RXi Pharmaceuticals Corporation, SciFluor Life Sciences, LLC, TCM Biotech International Corp, Vascular Biogenics Ltd., Virobay Inc. and XTuit Pharmaceuticals, Inc.

©http://www.rnrmarketresearch.com/ ; [email protected]

+1 888 391 5441


Liver fibrosis pipeline review h2 2015

Liver Fibrosis - Pipeline Review, H2 2015

Drugs Profile Discussed in this Research:

AIC-649, ANG-3281, ANG-4011, Antisense RNAi Oligonucleotide for Liver Fibrosis, BOT-162, CC-539, CC-90001, CIGB-500, CPI-43132, CT-140, DB-036, DCBBO-1202, disitertide, Drugs for Tissue Fibrosis, Drug to Inhibit Galectin-3 for Fibrosis, Drugs to Inhibit NADPH Oxidase for Influenza and Liver Fibrosis, elafibranor, F-351, FG-3019, GM-CT-01, m GRMD-02, HEC-00000585, HepaStem, INT-767, ISTH-0047, KW-1, LC-280126, melittin, MOR-8457, ND-L02s0201, noscapine, NPLC-0393, P-17, PBI-4050, PRM-151, PXS-4728A, PXS-5033A, Recombinant Enzyme to Replace MMP-9 for Liver Fibrosis and Pulmonary Fibrosis, RXI-209, RYI-018, selonsertib, simtuzumab, Small Molecule for Liver Fibrosis, Small Molecule to Antagonize GPR91 for Retinal Angiogenesis and Liver Fibrosis, Small Molecules for Fibrosis, Small Molecules to Antagonize Receptor Tyrosine Kinase for Liver Fibrosis, Stem Cell Therapy for Liver Fibrosis and Liver Cirrhosis, Synthetic Peptide to Inhibit RSK for Fibrosis and Oncology, TCM-808FB, VB-201, VBY-376 and VBY-825

©http://www.rnrmarketresearch.com/ ; [email protected]

+1 888 391 5441


Liver fibrosis pipeline review h2 2015

Liver Fibrosis - Pipeline Review, H2 2015

Scope For Liver Fibrosis - Pipeline Review, H2 2015

•The report provides a snapshot of the global therapeutic landscape of Liver Fibrosis

•The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

•The report reviews key players involved in the therapeutics development for Liver Fibrosis and enlists all their major and minor projects

•The report summarizes all the dormant and discontinued pipeline projects

•A review of the Liver Fibrosis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

•Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

•A detailed assessment of monotherapy and combination therapy pipeline projects

•Coverage of the Liver Fibrosis pipeline on the basis of target, MoA, route of administration and molecule type

©http://www.rnrmarketresearch.com/ ; [email protected]

+1 888 391 5441


Liver fibrosis pipeline review h2 2015

Liver Fibrosis - Pipeline Review, H2 2015

Reasons to Buy:

•Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

•Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

•Develop strategic initiatives by understanding the focus areas of leading companies

•Identify and understand important and diverse types of therapeutics under development for Liver Fibrosis

•Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

•Devise corrective measures for pipeline projects by understanding Liver Fibrosis pipeline depth and focus of Indication therapeutics

•Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

•Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

©http://www.rnrmarketresearch.com/ ; [email protected]

+1 888 391 5441


For more details contact mr ritesh tiwari sales@rnrmarketresearch com 18883915441

Liver Fibrosis - Pipeline Review, H2 2015

For more details contact Mr. Ritesh Tiwari :[email protected]/ +18883915441

RnRMarkertResearch

RnRMarketResearch.com, an online repository of market  research reports, offers in-depth analysis of over 5000 market segments. RnRMarket Research library has syndicated reports by leading market research  publishers across the globe.

©http://www.rnrmarketresearch.com/ ; [email protected]

+1 888 391 5441


  • Login